28.0005.41% ( -1.600 )
Delay Trading: Nov 17, 10:37:56Profile
About

HJ SCIENCE-B
06132.HK
HJ Science Co., Ltd. engages in research and development of new small molecule drugs in the People’s Republic of China. It focuses on autoimmune, metabolic diseases, and oncology disorders. The company’s core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the topical treatment of atopic dermatitis (AD), acne vulgaris (AV), neurodermatitis (ND), and psoriasis (PS), as well as oral treatment of AD, AV, ND, and PS in the autoimmune sector; HJ178, an orally available agent for type 2 diabetes, and potentially overweight or obesity in the metabolic sector; and HJ891, an oral KRAS inhibitor intended for the treatment of non-small-cell lung cancer.
Profile
- Company Name
- HJ Science Co., Ltd.
- Market
- SEHK
- Founded
- Industry
- --
- Fiscal Year End
- --
- Website
- www.hj3h.com
Related Securities
Industry
Industry RankingsValueRank
Management
NamePosition
